Understanding the Utility of Adjuvant Systemic Therapy for Primary Breast Cancer
- 15 February 2001
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (4), 972-979
- https://doi.org/10.1200/jco.2001.19.4.972
Abstract
PURPOSE: Physicians and patients require quantitative information on the expected benefits of adjuvant therapy for primary breast cancer to make appropriate treatment decisions. To date, there has not been any widely available method for estimating the benefits from adjuvant systemic therapy, in terms of long-term disease-free survival probabilities, in patients with primary breast cancer. METHODS: Baseline prognostic information for primary breast cancer patients was estimated by asking 11 breast cancer specialists to complete a questionnaire on baseline prognosis and then using mean values. Data on the relative benefits of adjuvant therapy were culled from systematic reviews and randomized controlled trials. A computer algorithm was developed to calculate 10-year absolute outcome data. Results from this evaluation were compared with a previously described actuarial algorithm. RESULTS: Individual prognostic estimates varied within a group of breast cancer specialists, but mean values of their estimates closely followed published data. Translation of expected benefits of adjuvant therapy from relative to absolute terms was performed with a simple computer algorithm. The data were translated into tabular forms to facilitate user-friendly clinical use. CONCLUSION: The provided data should facilitate a better understanding of the absolute magnitude of benefit for available systemic adjuvant therapies in individual women with primary breast cancer. This should allow patients to make more informed decisions about their options.This publication has 18 references indexed in Scilit:
- Time-dependence of hazard ratios for prognostic factors in primary breast cancerBreast Cancer Research and Treatment, 1998
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.Journal of Clinical Oncology, 1998
- How Can Prognostic and Predictive Factors in Breast Cancer Be Used in a Practical Way Today?Recent Results in Cancer Research, 1998
- Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.Journal of Clinical Oncology, 1993
- Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast CancerJNCI Journal of the National Cancer Institute, 1993
- Offering the Option of Randomized Clinical Trials to Cancer Patients Who Overestimate Their Prognoses with Standard TherapiesCancer Investigation, 1993
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 womenThe Lancet, 1992
- The Relation between Survival and Age at Diagnosis in Breast CancerThe New England Journal of Medicine, 1986